|
| | Issue Date | Title | Author(s) |
| 41 | 2023 | AML and FLT3: An update on FDA-approved or under review kinase inhibitors targeting FLT3 kinase | Nada Alaa El-Deen; Mai Jaballah; Abouzid, Khaled ; Dokla, Eman ; Serya, Rabah |
| 42 | 2023 | Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms | Ashraf, Rosaline; Serya, Rabah ; Abouzid, Khaled AM; Adel, Mai |
| 43 | 2023 | Hit Identification Against Candida Albicans: Design, Synthesis, Molecular Docking and Biological Evaluation of Hybrid Styryl-Quinoxaline Based Analogues. | Jaballah, Maiy Y; Alaraby, Mohamed; Serya, Rabah ; Abouzid, Khaled |
| 44 | 2024 | Advances in non-Hydroxamate based Histone Deacetylase Inhibitors as Anticancer Agents | Nabih, Nadine W; Jaballah, Maiy Y; Serya, Rabah ; Abouzid, Khaled AM |
| 45 | 15-Mar-2024 | Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells | Abdel-Aziz, Amal Kamal ; Ahmed, Tarek E.; Hatem, Yasmin; Abdel Rahman, Engy A.; Sharaky, Marwa; Shahin, Mai I. ; Elrazaz, Eman Z.; Serya, Rabah A.T. ; Henary, Maged; Ali, Sameh S.; Abou El Ella, Dalal A.; Dokla, Eman ; Helmy, Sama |
| 46 | Jun-2024 | Advances in the discovery of activin receptor-like kinase 5 (ALK5) inhibitors | Mansour, Mai A; Hassan, Ghaneya S; Jaballah, Maiy Y; Abouzid, Khaled A M; Serya, Rabah |
| 47 | Dec-2024 | Lead generation of Aurora-A kinase inhibitors: Using 3D-QSAR pharmacophore modeling, virtual screening, and molecular docking | Sara A. Hesham; Shahin, Mai I. ; Samar Mowafy; Rabah A. T. Serya ; Nahla A. Farag; Khaled A. M. Abouzid |
| 48 | 2025 | Next-Generation Diarylurea Antibacterials: From Structural Design and Optimization to Microbial Target Specific Strategies | Kassab, Rafif Rashad; Serya, Rabah Ahmed; Serya, Rabah ; Nermin Samir ; Abouzid, Khaled |
| 49 | May-2025 | Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML | El-Deen, Nada Alaa; DeFilippis, RosaAnna; Milik, Sandra N; Patel, Suhana; Ismail, Muhammad I; Khaled, Omar; Ahmed, Tarek Erfan; Abdelfattah, Ayatullah Gamal; Ali, Eslam M H; Gaballah, Maiy Y; McPhillie, Martin J; Abouzid, Khaled A M; Henary, Maged; Minucci, Saverio; Shah, Neil P; Abdel-Aziz, Amal Kamal ; Serya, Rabah ; Dokla, Eman |
| 50 | 1-Jul-2025 | Targeting DNA repair mechanisms: Spirobenzoxazinone and salicylamide derivatives as novel candidates for PARP-1 inhibition in cancer therapy | Kadry, Alaa Ahmed; Adel, Mai; Abubshait, Samar A; Yahya, Galal; Sharaky, Marwa; Abouzid, Khaled A M; Serya, Rabah |
| 51 | 1-Jul-2025 | Design and synthesis of novel Hydroxamate and non-Hydroxamate HDAC inhibitors based on Chromone and Quinazolone scaffolds | Ashraf, Rosaline; Adel, Mai; Ibrahim, Esraa; Haffez, Hesham; Soror, Sameh; Abouzid, Khaled A M; Serya, Rabah |
| 52 | Sep-2025 | Discovery of Furopyrimidine-Pyrazole Hybrid Compounds Targeting p53-MDM2 Interaction as Anticancer Agents | Mansour, Mai A; Hassan, Ghaneya S; Jaballah, Maiy Y; Dege, Necmi; Şahin, Onur; Sharaky, Marwa; Zhang, Xiaoliang; Su, Ruixin; Kong, Dexin; Abouzid, Khaled A M; Serya, Rabah |
| 53 | 1-Dec-2025 | Tackling microbial resistance with 4H-chromen-4-one derivatives as a novel class of penicillin binding protein 2a inhibitors | Shalaby, Menna-Allah W; Abutaleb, Nader S; Elgammal, Yehia; Liang, Hsin-Wen; Abdallah, Inas A; Fishovitz, Jennifer; Seleem, Mohamed N; Abouzid, Khaled A M; Serya, Rabah ; Dokla, Eman |
| 54 | 2026 | Design, synthesis, in silico, and biological evaluation of novel pyrazolopyrimidinone-based estrogen receptor inhibitors | Hesham, Sara A; Ziko, Laila; Serya, Rabah ; Farag, Nahla A; Mowafy, Samar; Shahin, Mai I; Abouzid, Khaled |
| 55 | May-2026 | Ligand-Based Design of Novel Thiazole-Quinazolinone Hybrids with Dual Antimicrobial and Anti-Virulence Activity Targeting Staphylococcal Sortase A | Hammad, Shaymaa G; Aboul-Magd, Dina S; Ghorab, Mostafa M; Adel, Mai; Serya, Rabah ; El-Hossary, Ebaa M; El-Gazzar, Marwa G; Abouzid, Khaled A M |
Loading...